Alterity Therapeutics Limited(ATHE)Earnings, Financials & Key Ratios
ATHE•NASDAQ
$4.52
$82M mkt cap·Price updated May 6, 2026
AboutAlterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.Show more
- Revenue$5M+35.3%
- EBITDA-$15M+25.7%
- Net Income-$12M+36.5%
- EPS (Diluted)-1.14+63.5%
- Gross Margin97.66%+3.2%
- EBITDA Margin-267.44%+45.1%
- Operating Margin-267.96%+45.1%
- Net Margin-223.35%+53.1%
- ROE-43.23%+58.6%
- ROIC-203.97%+40.6%
- Debt/Equity0.00-68.2%
ATHE Key Insights
Alterity Therapeutics Limited (ATHE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 80 (top 20%)
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 75.3% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ATHE Price & Volume
Alterity Therapeutics Limited (ATHE) stock price & volume — 10-year historical chart
Loading chart...
ATHE Growth Metrics
Alterity Therapeutics Limited (ATHE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years40.86%
5 Years-
3 Years2.01%
TTM4.63%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-17.32%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM39.09%
Return on Capital
10 Years-57.2%
5 Years-65.83%
3 Years-69.46%
Last Year-51.74%
ATHE Peer Comparison
Alterity Therapeutics Limited (ATHE) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRTA | 601.85M | 11.18 | -2.47 | -92.84% | -25.21% | -73% | 0.05 | |
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 SAVA | 94.44M | 1.96 | -3.76 | -95.77% | ||||
 AVXL | 309.52M | 3.34 | -6.19 | -31.55% | ||||
 IONS | 12.7B | 76.85 | -32.29 | 33.87% | -30.87% | -58.57% | 5.35 | |
 BIIB | 28.15B | 190.68 | 21.59 | 1.39% | 13.92% | 7.55% | 0.38 | |
 RARE | 2.55B | 25.93 | -4.45 | 20.13% | -91.03% | -6.08% | ||
 PTCT | 5.52B | 66.61 | 8.56 | 114.51% | 39.44% |
Compare ATHE vs Peers
Alterity Therapeutics Limited (ATHE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ATHE Income Statement
Alterity Therapeutics Limited (ATHE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 132.4K | 201.17K | 108.54K | 0 | 4.34M | 5.12M | 3.92M | 4.02M | 5.44M |
| Revenue Growth % | -7.19% | 51.95% | -46.05% | -100% | - | 18.06% | -23.56% | 2.63% | 35.32% |
| Cost of Goods Sold | 21.33K | 21.8K | 29.7K | 112.43K | 360.03K | 364.67K | 285.07K | 214.3K | 127.52K |
| COGS % of Revenue | 16.11% | 10.84% | 27.36% | - | 8.3% | 7.12% | 7.28% | 5.33% | 2.34% |
| Gross Profit | 111.07K▲ 0% | 179.38K▲ 61.5% | 78.84K▼ 56.0% | -112.43K▼ 242.6% | 3.98M▲ 3639.7% | 4.76M▲ 19.6% | 3.63M▼ 23.7% | 3.8M▲ 4.8% | 5.31M▲ 39.6% |
| Gross Margin % | 83.89% | 89.16% | 72.64% | - | 91.7% | 92.88% | 92.72% | 94.67% | 97.66% |
| Gross Profit Growth % | -7.33% | 61.5% | -56.05% | -242.6% | 3639.7% | 19.58% | -23.69% | 4.78% | 39.59% |
| Operating Expenses | 6.77M | 11.1M | 12.47M | 10.07M | 19.16M | 20.26M | 18.24M | 23.41M | 19.89M |
| OpEx % of Revenue | 5115.24% | 5516.24% | 11492.14% | - | 441.42% | 395.42% | 465.69% | 582.36% | 365.62% |
| Selling, General & Admin | 3.95M | 4.32M | 4.28M | 3.33M | 6.87M | 5.51M | 5.04M | 4.76M | 5.48M |
| SG&A % of Revenue | 2981.44% | 2147.03% | 3942.08% | - | 158.36% | 107.62% | 128.68% | 118.49% | 100.78% |
| Research & Development | 5.7M | 6.7M | 12.98M | 10.1M | 12.28M | 14.75M | 13.2M | 18.64M | 14.4M |
| R&D % of Revenue | 4305.52% | 3329.46% | 11961.88% | - | 283.06% | 287.81% | 337.01% | 463.86% | 264.84% |
| Other Operating Expenses | -241.89K | 0 | -4.79M | -3.36M | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -6.88M▲ 0% | -7.77M▼ 12.9% | -12.71M▼ 63.6% | -10.41M▲ 18.1% | -15.18M▼ 45.8% | -15.5M▼ 2.1% | -14.64M▲ 5.6% | -19.6M▼ 33.9% | -14.57M▲ 25.6% |
| Operating Margin % | -5197.94% | -3862.48% | -11713.74% | - | -349.77% | -302.56% | -373.72% | -487.69% | -267.96% |
| Operating Income Growth % | 19.86% | -12.91% | -63.62% | 18.09% | -45.75% | -2.13% | 5.59% | -33.93% | 25.65% |
| EBITDA | -6.86M | -7.75M | -12.68M | -10.3M | -15.16M | -15.45M | -14.6M | -19.57M | -14.55M |
| EBITDA Margin % | -5181.83% | -3851.64% | -11686.38% | - | -349.34% | -301.51% | -372.75% | -486.81% | -267.44% |
| EBITDA Growth % | 19.89% | -12.94% | -63.7% | 18.78% | -47.16% | -1.9% | 5.5% | -34.03% | 25.66% |
| D&A (Non-Cash Add-back) | 21.33K | 21.8K | 29.7K | 112.43K | 18.66K | 54.21K | 37.85K | 35.34K | 28.31K |
| EBIT | -6.88M | -8.2M | -12.8M | -13.46M | -15.18M | -17.45M | -14.64M | -19.61M | -14.66M |
| Net Interest Income | 0 | 0 | 0 | 17.12K | 20.68K | 2.5K | 16.44K | 268.42K | 446.29K |
| Interest Income | 132.4K | 201.17K | 108.54K | 17.12K | 20.68K | 2.5K | 16.44K | 268.42K | 446.29K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -786.28K | -127.86K | 324.64K | 428.68K | -133.04K | 2.72M | 904.68K | 524.33K | 2.49M |
| Pretax Income | -7.54M▲ 0% | -8.27M▼ 9.6% | -12.34M▼ 49.3% | -10.06M▲ 18.5% | -15.31M▼ 52.2% | -12.78M▲ 16.5% | -13.7M▼ 7.2% | -19.08M▼ 39.2% | -12.08M▲ 36.7% |
| Pretax Margin % | -5696.6% | -4108.75% | -11367.29% | - | -352.78% | -249.38% | -349.87% | -474.65% | -222.1% |
| Income Tax | 660.21K | -495.44K | -376.03K | -362.19K | 0 | 70.01K | 104.46K | 46.09K | 68.06K |
| Effective Tax Rate % | -8.75% | 5.99% | 3.05% | 3.6% | 0% | -0.55% | -0.76% | -0.24% | -0.56% |
| Net Income | -7.54M▲ 0% | -8.27M▼ 9.6% | -11.96M▼ 44.7% | -10.06M▲ 15.9% | -15.31M▼ 52.2% | -12.85M▲ 16.1% | -13.81M▼ 7.5% | -19.12M▼ 38.5% | -12.15M▲ 36.5% |
| Net Margin % | -5696.6% | -4108.75% | -11020.84% | - | -352.78% | -250.75% | -352.54% | -475.79% | -223.35% |
| Net Income Growth % | 2.43% | -9.59% | -44.72% | 15.9% | -52.19% | 16.08% | -7.47% | -38.51% | 36.48% |
| Net Income (Continuing) | -7.54M | -8.27M | -12.34M | -13.46M | -15.31M | -12.85M | -13.81M | -19.12M | -12.15M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -8.46▲ 0% | -9.30▼ 9.9% | -11.64▼ 25.2% | -6.48▲ 44.3% | -5.40▲ 16.7% | -3.18▲ 41.1% | -3.42▼ 7.5% | -3.12▲ 8.8% | -1.14▲ 63.5% |
| EPS Growth % | 2.76% | -9.93% | -25.16% | 44.33% | 16.67% | 41.11% | -7.55% | 8.77% | 63.46% |
| EPS (Basic) | -8.46 | -9.30 | -11.64 | -6.48 | -5.40 | -3.18 | -3.42 | -3.12 | -1.14 |
| Diluted Shares Outstanding | 889.82K | 889.82K | 1.03M | 1.49M | 2.83M | 4.01M | 4.05M | 6.08M | 10.66M |
| Basic Shares Outstanding | 889.82K | 888.79K | 1.03M | 1.49M | 2.83M | 4.01M | 4.05M | 6.08M | 10.66M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
ATHE Balance Sheet
Alterity Therapeutics Limited (ATHE) balance sheet — assets, liabilities & shareholders' equity
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 25.25M | 18.65M | 19.86M | 13.23M | 33.49M | 41.14M | 27.05M | 19.04M | 45.87M |
| Cash & Short-Term Investments | 21.93M | 15.25M | 14.4M | 9.2M | 28.12M | 34.81M | 15.77M | 12.64M | 40.66M |
| Cash Only | 21.88M | 15.24M | 14.4M | 9.2M | 28.12M | 34.81M | 15.77M | 12.64M | 33.16M |
| Short-Term Investments | 43.99K | 9.51K | 0 | 0 | 0 | 0 | 0 | 0 | 7.5M |
| Accounts Receivable | 3.04M | 3.15M | 4.83M | 61.32K | 4.13M | 4.67M | 8.65M | 4.04M | 3.94M |
| Days Sales Outstanding | 8.37K | 5.72K | 16.24K | - | 347.06 | 332.65 | 806.07 | 367.03 | 264.25 |
| Inventory | 241.63K | 256.82K | 621.74K | 567.88K | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 4.14K | 4.3K | 7.64K | 1.84K | - | - | - | - | - |
| Other Current Assets | 0 | 290 | 10.03K | 2.84M | 160.67K | 66.19K | 56.6K | 40.67K | 41.81K |
| Total Non-Current Assets | 30.82K | 71.42K | 48.75K | 71.37K | 96.81K | 218.52K | 268.86K | 186.88K | 155.17K |
| Property, Plant & Equipment | 30.82K | 71.42K | 48.75K | 71.37K | 96.81K | 218.52K | 268.86K | 186.88K | 155.17K |
| Fixed Asset Turnover | 4.30x | 2.82x | 2.23x | - | 44.83x | 23.45x | 14.57x | 21.51x | 35.05x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | -30.82K | -71.42K | -48.75K | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 25.28M▲ 0% | 18.73M▼ 25.9% | 19.91M▲ 6.3% | 13.3M▼ 33.2% | 33.59M▲ 152.4% | 41.36M▲ 23.2% | 27.32M▼ 34.0% | 19.22M▼ 29.6% | 46.03M▲ 139.4% |
| Asset Turnover | 0.01x | 0.01x | 0.01x | - | 0.13x | 0.12x | 0.14x | 0.21x | 0.12x |
| Asset Growth % | -25.04% | -25.93% | 6.32% | -33.17% | 152.43% | 23.16% | -33.96% | -29.63% | 139.42% |
| Total Current Liabilities | 1.59M | 2.64M | 3.32M | 2.71M | 3.07M | 5.82M | 4.38M | 5.37M | 3.53M |
| Accounts Payable | 65.05K | 1.33M | 1.69M | 954.03K | 1.45M | 2.64M | 1.72M | 581.14K | 538.28K |
| Days Payables Outstanding | 1.11K | 22.33K | 20.82K | 3.1K | 1.47K | 2.64K | 2.2K | 989.79 | 1.54K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | -32.88K | 0 | -57.63K | -107.18K | 0 | 0 |
| Other Current Liabilities | 698.04K | 11.19K | 11.72K | 43.84K | 33.84K | 2.5M | 169.02K | 4.12M | 876.05K |
| Current Ratio | 15.88x | 7.06x | 5.98x | 4.88x | 10.92x | 7.07x | 6.17x | 3.54x | 12.98x |
| Quick Ratio | 15.72x | 6.96x | 5.79x | 4.67x | 10.92x | 7.07x | 6.17x | 3.54x | 12.98x |
| Cash Conversion Cycle | 11.39K | -12.31K | 3.06K | - | - | - | - | - | - |
| Total Non-Current Liabilities | 440 | 916 | 34.98K | 42.38K | 47.67K | 73.61K | 122.71K | 51.91K | 88.55K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 868 | 37.9K | 59.86K | 103.21K | 51.91K | 88.55K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 440 | 916 | 34.98K | 41.51K | 9.77K | 13.75K | 19.5K | 0 | 0 |
| Total Liabilities | 1.59M | 2.64M | 3.36M | 2.76M | 3.12M | 5.89M | 4.5M | 5.43M | 3.62M |
| Total Debt | 0 | 0 | 0 | 33.75K | 65.65K | 117.49K | 210.38K | 159.04K | 155.46K |
| Net Debt | -21.88M | -15.24M | -14.4M | -9.16M | -28.05M | -34.69M | -15.56M | -12.48M | -33M |
| Debt / Equity | - | - | - | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | - |
| Total Equity | 23.69M▲ 0% | 16.08M▼ 32.1% | 16.55M▲ 2.9% | 10.55M▼ 36.3% | 30.47M▲ 188.9% | 35.47M▲ 16.4% | 22.81M▼ 35.7% | 13.8M▼ 39.5% | 42.4M▲ 207.3% |
| Equity Growth % | -24.48% | -32.12% | 2.95% | -36.28% | 188.88% | 16.4% | -35.68% | -39.52% | 207.31% |
| Book Value per Share | 26.62 | 18.07 | 16.13 | 7.07 | 10.77 | 8.85 | 5.64 | 2.27 | 3.98 |
| Total Shareholders' Equity | 23.69M | 16.08M | 16.55M | 10.55M | 30.47M | 35.47M | 22.81M | 13.8M | 42.4M |
| Common Stock | 144.02M | 143.91M | 156.63M | 160.7M | 197.45M | 213.79M | 213.97M | 223.15M | 262.95M |
| Retained Earnings | -122.65M | -129.58M | -141.24M | -151.02M | -169.73M | -181.88M | -195.13M | -214.16M | -225.89M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 2.32M | 1.75M | 1.16M | 866.12K | 2.75M | 3.57M | 3.97M | 4.81M | 5.34M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ATHE Cash Flow Statement
Alterity Therapeutics Limited (ATHE) cash flow — operating, investing & free cash flow history
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -5.87M | -6.25M | -13.95M | -9.43M | -17.33M | -12.34M | -20.04M | -12.61M | -11.45M |
| Operating CF Margin % | -4429.95% | -3104.37% | -12857.08% | - | -399.35% | -240.8% | -511.6% | -313.63% | -210.54% |
| Operating CF Growth % | 20.94% | -6.48% | -123.45% | 32.42% | -83.75% | 28.81% | -62.4% | 37.08% | 9.16% |
| Net Income | -7.54M | -8.27M | -12.34M | -10.06M | -15.31M | -12.85M | -13.81M | -19.12M | -12.15M |
| Depreciation & Amortization | 21.33K | 21.8K | 29.7K | 112.43K | 75.37K | 54.21K | 102.26K | 147.53K | 139.72K |
| Stock-Based Compensation | 24.46K | 764.54K | 89.14K | -12.02K | 1.88M | 1.51M | 966.57K | 881.95K | 979.92K |
| Deferred Taxes | 631.56K | -486.42K | -493.02K | -250.96K | 2.33M | -1.06M | 2.99M | 0 | 0 |
| Other Non-Cash Items | 24.46K | 764.54K | 89.14K | -12.02K | -2.1M | 455.57K | -6.35M | -261.15K | 190.62K |
| Working Capital Changes | 975.19K | 956.09K | -1.33M | 791.13K | -4.22M | -447.68K | -3.94M | 5.75M | -613.68K |
| Change in Receivables | 1.75M | -116.84K | -1.68M | 4.77M | -4.22M | -447.68K | -3.94M | 4.62M | 104.07K |
| Change in Inventory | -4.07K | 18.99K | -662.93K | 648.57K | 191.13K | -2.21M | 2.45M | 0 | 0 |
| Change in Payables | -856.13K | 1.16M | 662.93K | -648.57K | 432.9K | 2.6M | -1.56M | 1.1M | 0 |
| Cash from Investing | -27.92K | -18.42K | -7.02K | -16.74K | -10.47K | -89.15K | -36.46K | -5.72K | -7.5M |
| Capital Expenditures | -27.92K | -62.41K | -7.02K | -16.74K | -10.47K | -89.15K | -7.31K | -5.72K | 0 |
| CapEx % of Revenue | 21.09% | 31.02% | 6.47% | - | 0.24% | 1.74% | 0.19% | 0.14% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 43.99K | 0 | 0 | 0 | 0 | -29.15K | 0 | 0 |
| Cash from Financing | -159.56K | -107.68K | 12.72M | 3.98M | 36.69M | 16.3M | 124.34K | 9.22M | 39.67M |
| Debt Issued (Net) | 0 | 0 | 0 | -89.24K | -58.29K | -34.51K | -59.92K | -10.37K | -127.1K |
| Equity Issued (Net) | 0 | 0 | 1000K | 1000K | 1000K | 1000K | 316.68K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -159.56K | -107.68K | -362.32K | -292.77K | -2.49M | -836.97K | -132.41K | -918.02K | -2.77M |
| Net Change in Cash | -6.71M▲ 0% | -6.65M▲ 0.9% | -835.65K▲ 87.4% | -5.2M▼ 522.6% | 18.92M▲ 463.6% | 6.69M▼ 64.6% | -19.03M▼ 384.4% | -3.13M▲ 83.5% | 20.52M▲ 754.6% |
| Free Cash Flow | -5.89M▲ 0% | -6.31M▼ 7.0% | -13.96M▼ 121.3% | -9.45M▲ 32.3% | -17.34M▼ 83.5% | -12.43M▲ 28.3% | -20.04M▼ 61.3% | -12.61M▲ 37.1% | -11.45M▲ 9.2% |
| FCF Margin % | -4451.04% | -3135.39% | -12863.55% | - | -399.59% | -242.54% | -511.78% | -313.78% | -210.54% |
| FCF Growth % | 20.59% | -7.04% | -121.35% | 32.33% | -83.54% | 28.34% | -61.29% | 37.08% | 9.2% |
| FCF per Share | -6.62 | -7.09 | -13.60 | -6.33 | -6.13 | -3.10 | -4.95 | -2.07 | -1.07 |
| FCF Conversion (FCF/Net Income) | 0.78x | 0.76x | 1.17x | 0.94x | 1.13x | 0.96x | 1.45x | 0.66x | 0.94x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ATHE Key Ratios
Alterity Therapeutics Limited (ATHE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -21.93% | -27.4% | -41.57% | -73.3% | -74.23% | -74.65% | -38.97% | -47.38% | -104.47% | -43.23% |
| Return on Invested Capital (ROIC) | -184.6% | -225.45% | -439.72% | -635.59% | -441.32% | -598.31% | -726.68% | -273.44% | -343.18% | -203.97% |
| Gross Margin | 84.01% | 83.89% | 89.16% | 72.64% | - | 91.7% | 92.88% | 92.72% | 94.67% | 97.66% |
| Net Margin | -5418.28% | -5696.6% | -4108.75% | -11020.84% | - | -352.78% | -250.75% | -352.54% | -475.79% | -223.35% |
| Debt / Equity | - | - | - | - | 0.00x | 0.00x | 0.00x | 0.01x | 0.01x | 0.00x |
| FCF Conversion | 0.96x | 0.78x | 0.76x | 1.17x | 0.94x | 1.13x | 0.96x | 1.45x | 0.66x | 0.94x |
| Revenue Growth | -19.33% | -7.19% | 51.95% | -46.05% | -100% | - | 18.06% | -23.56% | 2.63% | 35.32% |
ATHE Frequently Asked Questions
Alterity Therapeutics Limited (ATHE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Alterity Therapeutics Limited (ATHE) reported $9.5M in revenue for fiscal year 2025. This represents a 1091% increase from $0.8M in 2002.
Alterity Therapeutics Limited (ATHE) grew revenue by 35.3% over the past year. This is strong growth.
Alterity Therapeutics Limited (ATHE) reported a net loss of $31.3M for fiscal year 2025.
Dividend & Returns
Alterity Therapeutics Limited (ATHE) has a return on equity (ROE) of -43.2%. Negative ROE indicates the company is unprofitable.
Alterity Therapeutics Limited (ATHE) had negative free cash flow of $23.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More ATHE
Alterity Therapeutics Limited (ATHE) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates